These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Utility of head and neck biopsies in the evaluation of posttransplant lymphoproliferative disorder. Campisi P; Allen UD; Ngan BY; Hawkes M; Forte V Otolaryngol Head Neck Surg; 2007 Aug; 137(2):296-300. PubMed ID: 17666259 [TBL] [Abstract][Full Text] [Related]
31. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157 [TBL] [Abstract][Full Text] [Related]
32. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children. Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323 [TBL] [Abstract][Full Text] [Related]
33. Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases. Chen W; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Weiss LM; Wang J Am J Clin Pathol; 2009 May; 131(5):632-9. PubMed ID: 19369621 [TBL] [Abstract][Full Text] [Related]
34. Unusual manifestation of posttransplant lymphoproliferative disorder in the esophagus. Kranz B; Vester U; Becker J; Woltering T; Wingen AM; Paul A; Hoyer PF Transplant Proc; 2006 Apr; 38(3):693-6. PubMed ID: 16647447 [TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764 [TBL] [Abstract][Full Text] [Related]
36. Involvement of the gastrointestinal tract by Epstein-Barr virus--associated posttransplant lymphoproliferative disorders. Nalesnik MA Am J Surg Pathol; 1990; 14 Suppl 1():92-100. PubMed ID: 2158245 [TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Birkeland SA; Hamilton-Dutoit S; Bendtzen K Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical analysis and Epstein-Barr virus in the tonsils of transplant recipients and healthy controls. Mowry SE; Strocker AM; Chan J; Takehana C; Kalantar N; Bhuta S; Shapiro NL Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):936-9. PubMed ID: 18794437 [TBL] [Abstract][Full Text] [Related]
39. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Babel N; Vergopoulos A; Trappe RU; Oertel S; Hammer MH; Karaivanov S; Schneider N; Riess H; Papp-Vary M; Neuhaus R; Gondek LP; Volk HD; Reinke P Transplantation; 2007 Aug; 84(3):387-91. PubMed ID: 17700165 [TBL] [Abstract][Full Text] [Related]
40. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. AlDabbagh MA; Gitman MR; Kumar D; Humar A; Rotstein C; Husain S Am J Transplant; 2017 Mar; 17(3):770-781. PubMed ID: 27545492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]